Free Trial

SCYNEXIS (SCYX) Competitors

SCYNEXIS logo
$0.81 0.00 (-0.30%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$0.82 +0.01 (+0.74%)
As of 10/15/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYX vs. HURA, TVGN, OVID, ATOS, BMEA, ZYBT, KLRS, IKT, VIRI, and TIL

Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include TuHURA Biosciences (HURA), Tevogen Bio (TVGN), Ovid Therapeutics (OVID), Atossa Genetics (ATOS), Biomea Fusion (BMEA), Zhengye Biotechnology (ZYBT), Kalaris Therapeutics (KLRS), Inhibikase Therapeutics (IKT), Virios Therapeutics (VIRI), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry.

SCYNEXIS vs. Its Competitors

TuHURA Biosciences (NASDAQ:HURA) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

TuHURA Biosciences presently has a consensus target price of $12.67, suggesting a potential upside of 394.79%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe TuHURA Biosciences is more favorable than SCYNEXIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TuHURA Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
3.00
SCYNEXIS
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

TuHURA Biosciences has a net margin of 0.00% compared to SCYNEXIS's net margin of -599.05%. SCYNEXIS's return on equity of -43.04% beat TuHURA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
TuHURA BiosciencesN/A -248.79% -150.83%
SCYNEXIS -599.05%-43.04%-28.21%

In the previous week, SCYNEXIS had 5 more articles in the media than TuHURA Biosciences. MarketBeat recorded 6 mentions for SCYNEXIS and 1 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.83 beat SCYNEXIS's score of 0.78 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
TuHURA Biosciences Positive
SCYNEXIS Positive

SCYNEXIS has higher revenue and earnings than TuHURA Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TuHURA BiosciencesN/AN/A-$21.68MN/AN/A
SCYNEXIS$3.75M9.05-$21.29M-$0.40-2.03

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 0.2% of TuHURA Biosciences shares are held by company insiders. Comparatively, 4.9% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

TuHURA Biosciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Summary

SCYNEXIS beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks.

Get SCYNEXIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCYX vs. The Competition

MetricSCYNEXISMED IndustryMedical SectorNASDAQ Exchange
Market Cap$34.06M$2.96B$6.11B$10.45B
Dividend YieldN/A57.77%5.73%4.77%
P/E Ratio-2.0222.7985.3627.36
Price / Sales9.05783.65596.99137.58
Price / CashN/A172.6337.4661.86
Price / Book0.565.5112.286.81
Net Income-$21.29M$33.06M$3.32B$276.80M
7 Day Performance2.32%0.23%0.59%0.42%
1 Month Performance-23.58%14.73%10.54%7.86%
1 Year Performance-47.40%-1.42%70.62%41.24%

SCYNEXIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCYX
SCYNEXIS
0.654 of 5 stars
$0.81
-0.3%
N/A-46.4%$34.06M$3.75M-2.0260News Coverage
Analyst Forecast
Gap Up
High Trading Volume
HURA
TuHURA Biosciences
1.671 of 5 stars
$2.49
-4.2%
$12.67
+408.7%
N/A$132.87MN/A0.00N/A
TVGN
Tevogen Bio
2.8464 of 5 stars
$0.65
-3.7%
$10.00
+1,441.3%
-44.9%$132.56MN/A-3.413News Coverage
OVID
Ovid Therapeutics
4.5389 of 5 stars
$1.79
-2.7%
$3.10
+73.2%
+43.5%$130.84M$6.65M-3.3860
ATOS
Atossa Genetics
2.6126 of 5 stars
$1.00
-1.0%
$6.25
+525.0%
-26.6%$130.46MN/A-4.358News Coverage
Analyst Downgrade
Gap Up
BMEA
Biomea Fusion
3.3413 of 5 stars
$2.67
+24.2%
$9.50
+255.8%
-85.0%$127.94MN/A-0.8850High Trading Volume
ZYBT
Zhengye Biotechnology
N/A$2.88
+7.5%
N/AN/A$126.41M$25.53M0.00278News Coverage
Analyst Forecast
KLRS
Kalaris Therapeutics
1.3786 of 5 stars
$8.03
+20.9%
$3.00
-62.6%
N/A$124.18MN/A0.00110High Trading Volume
IKT
Inhibikase Therapeutics
0.053 of 5 stars
$1.62
-2.4%
N/AN/A$123.70M$260K0.006Gap Down
VIRI
Virios Therapeutics
N/A$6.41
-0.2%
$5.00
-22.0%
+70.5%$123.44MN/A-23.745News Coverage
TIL
Instil Bio
3.3063 of 5 stars
$18.43
+1.8%
$88.50
+380.2%
-47.6%$122.19MN/A-1.43410Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:SCYX) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners